PLATELET-AGGREGATION, ATP RELEASE AND CYTOPLASMIC CA2- THE EFFECTS OFCLORICROMENE( MOVEMENT )

A placebo-controlled, double-blind, randomized, cross-over study was p erformed in 24 healthy volunteers. 12 volunteers received Cloricromene (100mg gastroresistant capsules twice a day) for 7 days, the other vo lunteers received identical placebo capsules. Subsequently, after a 7- day wash-out period, at day 15, each subject received the other treatm ent. Blood samples were taken on days 1 and 15 (1st day of each treatm ent) as well as on days 7 and 21 (7th day of each treatment) before th e morning drug administration and 2 and 4 hours later. Platelet aggreg ation and ATP secretion were studied in whole blood (WB) using ADP and collagen as stimulating agents. Ca2+ fluxes were studied in aequorin- loaded, washed platelets stimulated with ADP and collagen, while aggre gation in platelet-rich plasma (PRP) was studied using PAF, ADP and ad renaline as agonists. Consistent inhibition of aggregation and release induced by both ADP and collagen was observed in WB after Cloricromen e administration. Similarly, Ca2+ flux was also inhibited after drug a dministration. Platelet aggregation in PRP was inhibited only after 7 days of Cloricromene treatment with ADP and adrenaline as stimuli. We conclude that oral administration of Cloricromene leads to significant antiplatelet activity in healthy volunteers, in particular when plate lets are studied in the presence of other blood elements.